Healthcare
Biden admin appeals in case to force doctors, hospitals to perform transgender procedures even if unwilling
On Tuesday, the Biden administration filed an appeal aiming to require doctors and hospitals to carry out possibly harmful transgender-related procedures and surgeries, even if they are unwilling to.
A North Dakota judge in January sided with Catholic hospitals in striking down the Biden administration’s move to punish doctors who don’t perform transgender-related procedures for “sex discrimination,” according to Luke Goodrich, Vice President and senior counsel at BECKET Law. The administration filed an appeal on Tuesday.
Goodrich took to Twitter to outline his arguments about the administration’s move, which he vehemently opposes:
The plaintiffs are religious doctors, hospitals, and clinics who joyfully serve ALL patients regardless of sex or gender identity. They routinely provide top-notch care to transgender patients for everything from cancer to the common cold.
They also provide millions of dollars in free and low-cost care to the elderly, poor, and underserved–care that is jeopardized by the government’s attempt to punish them with multi-million dollar penalties.
The Transgender Mandate not only threatens religious doctors and hospitals. It also threatens patients, as there is ample evidence that certain gender transition procedures can be deeply harmful.
Multiple federal courts have reached the same conclusion: “There is no medical consensus that sex reassignment surgery is a necessary or even effective treatment for gender dysphoria.” Gibson v. Collier, 920 F.3d 212, 223 (5th Cir. 2019).
The government’s own doctors during the Obama Admin agreed: “Based on a thorough review of the clinical evidence…there is not enough evidence to determine whether gender reassignment surgery improves health outcomes for [patients] with gender dysphoria.
And just weeks ago, a study commissioned by NHS England found “very low” evidence for the effectiveness of “puberty blockers” and cross-sex hormones.
The Biden Admin shouldn’t have appealed. But we look forward to another ruling that protects patients, aligns with current medical research, and ensures doctors aren’t forced to violate their religious beliefs and professional medical judgment.
You can follow Douglas Braff on Twitter @DouglasPBraff.
Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.
Foreign Desk News writes:
Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.
“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.
Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.
“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.
The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages. https://t.co/8XvOuJzSL4
— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023
Foreign Desk News adds:
The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.
-
Featured7 days agoDHS Alert: suspected terrorist on southwest border poses ‘imminent’ national security threat to U.S.
-
China7 days agoTreasury Department sanctions Chinese companies, Mexican individuals as ‘enablers’ to fentanyl crisis
-
Healthcare7 days agoOklahoma Mother Sues School District After Alleged Assault by Trans Student
-
Economy3 days agoNew York City Mayor Eric Adams Proposes Housing Asylum Seekers in Private Homes
